Cargando…
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as (177)Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prosta...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099330/ https://www.ncbi.nlm.nih.gov/pubmed/35553387 http://dx.doi.org/10.1007/s40291-022-00594-2 |